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INTRODUCTION
Diltiazem hydrochloride (DH) is a calcium channel blocker 
that relaxes vascular smooth muscle and dilates coronary 
arteries by altering the calcium flux into the cell.[1] It has 
been used widely in the treatment of angina pectoris, 
hypertension, and cardiac arrhythmias.[2] Conventional oral 
dosage forms of DH are intended to administer dose of 
30 mg for four times a day or 60 mg thrice a day. Thus, 
attempts have been made to develop twice a day of oral 
sustained release dosage formulation for achieving better 
patient compliance and relative constant blood levels. 
It is readily absorbed from the gastrointestinal tract and 
undergoes substantial first-pass metabolism. The systemic 
bioavailability of the immediate-release preparation is 
approximately 40%-50%, with an elimination half-life 
of 3.5-7 h.[3] Sustained-release DH has been reported to 
reduce tachycardia without inducing excessive bradycardia 
and does not significantly reduce baseline heart rate below 
74 beats/min.[4] Because  of its low bioavailability and short 
half-life attempts have been made to develop sustained 
release products and a reduced dosing frequency.[5]
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In the last few decades, many types of peroral-modified/
controlled release formulations have been developed to 
decrease dosing frequency and enhance patient compliance, 
reduce fluctuation in circular drug levels, facilitate a more 
uniform effect, and improve the clinical efficacy of the 
drug. These formulations are designed to deliver the drugs 
at a controlled and predetermined rate, thus maintaining 
their therapeutically effective concentrations in the systemic 
circulations for prolonged periods of time.[6,7] There are a 
few reports on the formulation of oral-controlled release 
products of diltiazem employing coated beads,[8] pan 
coating,[9] microencapsulation,[10] and complexation.  [11] 
But due to growing interest in the development of 
homogeneous monolithic drug delivery system for various 
routes of administration, a very attractive type of dosage 
form like ‘microspheres’ is required.
Microspheres are solid approximately spherical particles 
ranging from 1 to 100 mm in size to provide advantages 
over sustained release tablets such as ready distribution 
over a large surface area, predictable and reproducible drug 
release kinetics, delocalization of total dose in GIT, reduced 
side effects of drug, and independent drug release rate on 
gastric transit time.[12,13] Oral multi-unit dosage forms like 
microspheres have received much attention as modified/
controlled drug delivery systems to attribute more 
uniformly in the gastro-intestine tract, thus resulting more 
uniform drug absorption and reducing patient-to-patient 
variability.[14-17] The multi-particulate systems can be filled 
into hard gelatin capsules or compressed into tablets. 
It has been reported that the selection of the proper 
microencapsulation technique and of the excipients, 
such as polymers as carriers, coaters, and emulsifiers, is 
very popular in the preparation of the modified release 
microspheres of the drug.[14-20] In last few years, a number 
of studies have been made on the compression of 
microparticles, such as microspheres, microcapsules, and 
microsponges into tablets, and the effects of excipients and 
of the compression on the drug release rate from these 
formulations have been investigated.[18-23] However, not 
a single study has been done on the filling of the matrix 
type microspheres of DH as compared to few studies on 
the tableting of the matrix type microspheres of DH.[24]
Natural biodegradable polymeric-based microspheres as a 
drug carrier are widely used as they improve the safety and 
efficacy of drug delivery, drug targeting to specific cells 
or organs, and better patient compliance. Egg albumin 
can be used as a carrier for microsphere formulation of 
drugs as it has properties of protein binding and physical 
entrapment, the passive and facilitated release process of 
various types of incorporated drugs from the albumin 
matrix. To overcome rapid dissolution of highly soluble 
polymer ‘egg albumin’ in aqueous environment, different 
cross-linking methods have been used for microsphere 
preparation. Ethylcellulose, which is one of the most widely 
used water-insoluble polymers, in modified release dosage 
forms, was chosen as the matrix-forming polymer due to 
its good compressibility, excellent physicochemical stability, 
and minimum toxicity.[15,17]
Hence, the purpose of the present research was to develop 
microspheres of DH to reduce its dosing frequency using 
egg albumin as a biodegradable, biocompatible carrier and 
an ethylcellulose as a coating polymer by the w/o emulsion 
thermal cross-linking method with a goal of delivering the 
same dose of the drug through microspheres in a capsule 
taken once rather than two or three times a day.
MATERIALS AND METHODS
Materials
Diltiazem hydrochloride was a gifted from Cadila 
Pharmaceutical Ltd., Ahmedabad, India. Egg albumin 
flakes and light paraffin oil of Laboratory Rasayana 
grade were procured from Ases laboratory, India, and 
Gujarat Pharmaceuticals Ltd., India, respectively. All other 
chemicals and solvents used were of analytical grade. The 
distilled water used was prepared in our laboratory.
Methods
Preparation of  egg albumin microspheres
Egg albumin microspheres of DH were prepared by 
the w/o emulsion thermal cross-linking method with 
minor modification.[25-29] Hundred ml of light paraffin 
oil was placed in a glass beaker and mixed with 0.4% 
w/v span 60 solution by stirring and heating at 708C for 
solubilization. The mixture was allowed to cool at room 
temperature. Add 10 ml of egg albumin aqueous solution 
of a different drug to polymer ratio ((1.0:1.0, 1.0:1.5 
and 1.0:2.0) drop wise (various concentrations 5% w/v, 
7.5% w/v, 10% w/v, and 15% w/v) to the different using a 
22-gauge hypodermic syringe into an external phase. Light 
paraffin was stirred at 600 rpm for 10 min with the help of 
a magnetic stirrer (Remi equipment, 5 l capacity, Mumbai, 
India). A w/o emulsion was formed. The temperature 
of the oil bath was raised to 958C {as preliminary study 
was carried out at four different temperature levels 
(308C, 608C, 808C and at 958C), indicating small, spherical 
highest percentage yielding microspheres with moderate 
aggregation at 958C} and stirring was continued until 
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were then separated by decantation and washed six times 
with 20 ml of petroleum ether for 2 min at 700 rpm to 
remove traces of oil. Finally, microspheres were washed 
three times with 60 zz  ml of distilled water for 2 min 
at 700 rpm and dried at room temperature (at 25°C 6   
0.58C, 60% RH) for 24 h. After drying, a fine yellow free 
flowing powder was obtained that was stored in desiccators 
at room temperature. Different batches of microspheres 
were prepared using different concentrations of surfactant 
(span 60; 0.2% wt/vol, 0.4% wt/vol, and 0.6% w/v) 
and different drug to egg albumin ratios (1.0:1.0, 1.0:1.5 
and 1.0:2.0). In each case, the other variables were kept 
constant. Average size of microspheres was determined 
by using a calibrated stage micrometer. A total of nine 
batches, each in triplicate, were prepared as per 32 factorial 
designs.
Determination of  percentage drug entrapment
Efficiency of drug entrapment for each batch was calculated 
in terms of percentage drug entrapment (PDE) as per the 
formula: PDE 5 100 (practical drug loading/theoretical 
drug loading). Theoretical drug loading was determined 
by calculation assuming that the entire drug present in the 
egg albumin solution gets entrapped in microspheres and 
no loss occur at any stage of preparation of microspheres. 
Practical drug loading was determined by crushing 100 mg 
of DH loaded egg albumin microspheres in a dry glass 
mortar containing 100 ml of distilled water. Resultant 
dispersion was kept aside for 3 h and 1 h in a sonicator. 
The dispersion was filtered through whatman filter paper 
(0.22 mm) and the filtrate was analyzed by using a UV/ Vis 
spectrophotometer (Hitachi U-2000) at 236.5 nm after 
suitable dilution with distilled water.[30]
Determination of  mean particle size and particle size distribution  (1)
The microspheres were characterized for size distribution 
by a simple optical microscope (Labomed CX RIII, India), 
using a calibrated stage micrometer. Geometric mean 
diameter (GMD) in mm was calculated using the formula: 
Xg 5 10 (ni log Xi)/N) where, Xg is the geometric mean 
diameter, ni is the number of particles in the range, Xi is 
mid-point of the range, and N is the total number of 
microspheres (N 5 500).[31]
In vitro drug release studies
Release of DH from the prepared batches of microspheres 
were studied in distilled water (900 ml) as prescribed for 
diltiazem hydrochloride sustained release dosage forms in 
USP XXIV using apparatus I. To mimic the stomach and 
intestinal environments conditions, in vitro release study[32] 
was also carried out for the optimized best batches of 
microspheres using USP dissolution rate test apparatus 
(Apparatus I, 100 rpm, 37 6 0.58C) for the first 2 h in pH 
1.2 buffer (900 ml simulated gastric fluid without enzyme) 
and then dissolution medium was replaced with pH 7.4 
phosphate buffer (900 ml) without enzyme and tested 
for the drug release for another 10 h.[32-34] A muslin cloth 
(200#) was tied over the basket to prevent slippage of 
microspheres from the basket during all dissolution studies. 
Microspheres equivalent to 90 mg of DH in Hard gelatin 
capsules (transparent, 0 size) were used for dissolution 
studies. 10 ml of the dissolution sample was withdrawn 
at different time intervals, filtered through a 0.45 mm 
membrane filter and replaced with an equal quantity of 
fresh dissolution medium. The samples were suitably 
diluted with dissolution fluid and analyzed for DH content 
spectrophotometrically at 236.5 nm. Percentage drug 
dissolved at different time intervals was calculated using 
the Beer’s-Lambert equation (Y 5 0.05125X 1 0.0335, 
R2 5 0.997). The time required for 80 % drug release (t80) 
was calculated using Korsmeyer and Peppas model.[35,36]
Confirmation test for cross-linking
Confirmation of thermal cross-linking of DH loaded egg 
albumin microspheres was done by solubility and biurate 
test methods.[37]
Optimization using factorial design
In this investigation, the drug to polymer ratio and surfactant 
concentration were selected as independent variables, 
whereas drug loading was chosen as dependent variables. 
The other variables such as volume of light paraffin oil 
(100 ml), volume of aqueous albumin solution (10 m 
of 7.5% w/v), thermal cross-linking temperature (958C), 
thermal cross-linking time (60 min), and stirring speed 
(600 rpm) were kept constant. The formulation parameters 
and % yield of the factorial design batches (F1 to F9) are 
shown in Table 1.
Coating to egg albumin microspheres of  diltiazem hydrochloride
To get desired sustained drug release from the microspheres, 
the burst effect of drug release should be reduced. Hence, 
egg albumin microspheres of optimized batch F2 (highest 
drug loading and good sphericity of microspheres) 
was taken for in situ coating using enteric polymer 
ethylcellulose. Coating solution of ethylcellulose of 
difference concentration (2.5%, 5.0% and 7.5% w/v) 
was prepared in acetone with dibutyl phthalate (2% v/v 
of polymer) as a plasticizer. It was added drop wise 
to the dispersion containing DH-loaded egg albumin 
microspheres. The system was stirred for 30 min, filtered 
(0.45 m size filter medium), washed six times with 6 ml 
volumes of petroleum ether, and dried at room temperature 
(258C 6 0.58C, 60% RH) for 24 h. A total of three batches, 
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each in triplicates, were prepared to optimize the percentage 
ethylcellulose coating on batch F2 microspheres.
Stability studies
To assess long-term stability,[38] the ethylcellulose-coated 
egg albumin microsphere formulations in triplicate 
(batch C3 of 7.5% w/v ethylcellulose coating) were put 
in hard gelatin capsules (transparent, 0 size) and sealed in 
aluminum packaging coated inside with polyethylene. The 
studies were performed at 408C/75% RH in the stability 
chamber (Stability Oven, Nirmal Instruments, Delhi, India) 
for 3 months. At the end of storage period, the formulation 
was observed for physical appearance, size, shape, surface 
morphology, drug content, and in vitro drug release studies.
Comparison of  in vitro drug release of  optimized egg albumin 
microsphere, batch C1 to C3 and market formulation
In vitro dissolution study in triplicate was carried out for the 
coated microsphere batches (C1, C2, and C3) and uncoated 
DH-loaded egg albumin microspheres, using the same 
method as described earlier in comparison to market 
formulation of DH microspheres (90 mg Angezem® 
CD; Capsule: Aztec: Sun Pharmaceutical Research center, 
Baroda, Gujarat, India).
RESULTS AND DISCUSSION
Preliminary trials
The presence of 0.4% w/v span 60 (HLB 5-6) was found 
to be essential to minimize aggregation of egg albumin 
droplets during the emulsification step and effective to 
achieve spherical, small, regular, discrete microspheres with 
good yield. The type and quality of the oil phase played an 
important role in controlling the diameter of microspheres. 
Two types of liquid paraffin (light or heavy) and cottonseed 
oil were tried. When cottonseed oil and heavy liquid paraffin 
were used, greater resistance was offered in the process of 
dispersion, leading to the formation of aggregated irregular-
shaped microspheres compared to that of light liquid 
paraffin. Thus, light liquid paraffin oil was selected and effect 
of its volume (75, 100, and 150 ml) on the characteristics 
of microspheres was studied. Discrete, small, regular, and 
spherical microspheres were obtained when 100 ml of light 
paraffin oil was used. To study the effect of stirring speed, 
microspheres were prepared at 100, 250, and 600 rpm. 
Microspheres with good sphericity were obtained at 600 rpm.
The geometric mean diameter of egg albumin microspheres 
varied from 47.30 6 1.5 mm to 59.65 6 1.6 mm with varying 
egg albumin concentration. The average percentage drug 
entrapment was found to be 69.6 6 4% in all the microsphere 
formulations. The highest drug loading efficiency was found 
with 7.5% w/v egg albumin. Three different ratios of drug 
to egg albumin (1.0:1.0, 1.0:1.5 and 1.0:2.0 wt/wt) were tried. 
Microspheres prepared using the 1.0:1.0 wt/wt drug to egg 
albumin ratio showed highest t80 (389 min), % drug entrapment 
efficiency (79.20%), and small (GMD: 47.30 6 1.5), spherical, 
discrete microspheres. A higher concentration of egg albumin 
produced a more viscous dispersion, which formed larger 
droplets and consequently larger microspheres as reported by 
Pongpaibul et al.[39] However, the microspheres showed a burst 
effect (55% drug release in 1 h) and a relatively faster drug 
release thereafter (total drug release in 6 hour). In situ coating 
of microspheres with ethylcellulose significantly reduced the 
burst effect (5% drug release in 1 h).
Table 1: A 32 full factorial design layout
Batch code Variable levels in coded forms Y60 (%) Y360 (%) t8 t50 Drug entrapment
efficiency (%)
GMD 6 SD
(mm)   X1 X2
F1 21 21 55.17 78.42 367 54 61.76 52.13 6 1.1
F2 21 0 57.00 78.08 369 53 79.2 47.30 6 1.5
F3 21 1 56.22 78.73 366 53 65 46.50 6 2.1
F4 0 21 51.65 79.16 363 58 59.5 61.40 6 2.6
F5 0 0 50.45 77.29 37 360 62.25 47.50 6 1.9
F6 0 1 50.38 78.13 369 60 52.5 47.10 6 3.1
F7 1 21 48.96 76.01 379 61 55.5 74.41 6 2.5
F8 1 0 48.23 76.81 375 62 58.25 66.63 6 2.8
F9 1 1 47.14 75.42 382 64 48 59.65 6 1.6
Translation of coded levels in actual units
Variable level Low (21)  High (11)
Drug to polymer 
ratio (X1)
1.0:1.0 1.0:2.0
Surfactant 
concentration (X2)
0.2 0.6
Y60, Y360 5 the percentage drug released in 60 min and 360 min, t80 5 the time in minutes required for 80% drug dissolution All the batches were prepared using 10 ml 7.5% w/v 
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Effect of emulsifier concentration on characteristics 
of microspheres
The geometric mean diameter of microspheres was found 
to vary from 52.13 6 1.1 mm to 46.50 6 2.1 mm on varying 
emulsifier (Span 60) concentration. Increased surfactant 
concentration led to the formation of microspheres with 
a lower GMD as reported by Chemtob et al.[37] Increasing 
Span 60 concentration from 0.2% to 0.6% wt/vol led 
to stabilization of the emulsion droplets avoiding their 
coalescence, resulting in smaller microspheres.[40,41] The 
drug loading efficiency varied from 60.70 6 0.9% to 
78.13 6 1.3% with varying emulsifier concentration 
from 0.2% to 0.6% during preparation of egg albumin 
microspheres.
The GMD of egg albumin microspheres decreased from 
61.71 6 2.0 mm to 47.30 6 1.5 mm with increasing speed 
of the magnetic stirrer from 100 rpm to 600 rpm. This 
result was expected because high stirring rates provide 
the shearing force needed to separate the oil phase into 
smaller globules. The stirring speed of 600 rpm was found 
to be optimum for egg albumin microspheres, as the drug 
loading efficiency was 78.21 6 1.6% at this speed. High 
stirring speed produced an irregular shape of microspheres, 
but an increased drug entrapment efficacy was found. 
Stirring time of 60 min was found to be optimum for 
egg albumin microspheres because at this time period, 
the microsphere size was small with good drug loading 
efficiency of 70.25 6 1.2%.
Effect of cross-linking temperature and time on 
microspheres
An increase in cross-linking temperature from 608C 
to 958C leads to a decrease in GMD. This is due to 
increase in the degree of congealing or rigidization of 
egg albumin[42] that ultimately results in shrinking of the 
particles irrespective of the cross-linking time. Increase 
cross-linking time from 60 min to 120 min irrespective 
to cross-linking temperature did not show any significant 
change in GMD. At 958C cross-linking temperature, 
cross-linking time of 60 min was enough for conversion 
of water from liquid state to vapor and hence complete 
removal of water present in the dispersed phase. This 
process starts essentially when the time of cross-linking is 
nearly 50 min, indicating no need to increase cross-linking 
temperature to get discrete spherical small with high 
percentage drug loading microspheres. Further increase 
in cross-linking time at the same temperature did not give 
the desired product characteristics but showed a step fall 
in the drug entrapment efficiency; it may be due to the loss 
of the drug present on the surface of the microspheres 
to the dispersion medium. It is surface-bound drug that 
is loosely held and usually lost to the externally oily phase 
during preparation or to solvents during the washing 
stage.[43] Increase in cross-linking time at constant cross-
linking temperature did not have a significant effect on 
the % drug loading.
Full factorial design
The results depicted in Table 1 clearly indicate that the 
selected dependent variables are strongly dependent on the 
selected independent variables as they show a wide variation 
among the nine batches (F1 to F9). The main effects 
(X1 and X2) represent the average result of changing one 
factor at a time from its low to high value. The interactions 
(X1X2) show how the response value changes when the two 
factors are simultaneously changed. The polynomial terms 
(X1X1 and X2X2) were included in the model to investigate 
non-linearity. The fitted equations (full models) relating 
the response, i.e. the %drug loading efficiency, to the 
transformed factor are shown in Table 1. The polynomial 
equations can be used to draw conclusions after considering 
the magnitude of coefficient and the mathematical sign 
it carries, i.e. positive or negative. The high value of 
correlation coefficient [Table 1] for the dependent variable 
indicates a good fit. The equation may be used to obtain 
estimates of the response since small error of variance was 
noticed in the replicates.
The polynomial equations relating the responses Y60 and t80 
to the transferred factors are:
Y60 5 51.031124.01X120.34X220.7175X1 X2 1 1.2933 
X1X120.3067X2X2
(r 5 0.9930, DF 5 8, F 5 42.74)  (2)
t80 5 369.22 1 5.66X1 1 1.333X2 1 1.00X1X2 1 4.667X1X1 
21.3333X2X2
(r 5 0.8970, DF 5 8, F 5 2.47)  (3)
The response values for the nine batches showed a wide 
variation; Y60 ranged from 47.14 to 57.00% and t80 ranged 
from 291 to 395 min. The data clearly indicate that Y60 and 
t80 values depend significantly on the selected independent 
variables. The high value of correlation coefficient 
(r 5 0.8970 for t80 and r 5 0.9930 for Y60) indicates a good fit. 
The equation (2) represents that the coefficients associated 
with X1 carry a negative sign. The Y60 was found to be 
inversely related to the polymer to drug ratio. Figures 1-4 
show the response surface plots drawn using Sigma Plot 
software (Jandel Scientific Software, San Rafael, CA).32   J Young Pharm Vol 2 / No 1
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Kinetic modeling of drug release
The method of Bamba et al. was adopted to decide 
the most appropriate model.[44] For the optimize batch 
(Batch F2), the release profile fitted to the Korsmeyer and 
Peppas model (F 5 4.41) giving the least residual sum of 
squares as compared to the Weibull model (F 5 6.03) and 
Higuchi model (F 5 98.83). This superiority is, however, 
statistically insignificant as shown by the F-ratio test. 
For the batch F2, the values of correlation coefficient 
were found to be 0.97, 0.97, and 0.94 for Korsmeyer and 
Peppas, Weibull, and Higuchi models, respectively. Out 
of nine batches, the Korsmeyer and Peppas model fitted 
well to all batches except one. Thus, the Korsmeyer and 
Peppas model was selected. For the Korsmeyer and Peppas 
model, the values of slope and intercept were found to 
be 0.5219 and 20.7548, respectively. From the value of 
slope (n 5 0.5219, 0.45 , n , 0.89), it can be concluded 
that the drug is released by diffusion of anomalous type 
(non-Fickian).
Selection of best batch
An ideal modified formulation is one from which a 
loading dose (,30%) is released in the first hour and 
the remaining 70% of the drug is released thereafter 
at a constant rate (6.36% per hour). The following 
constraints were chosen for the selection of the 
best batch; Y60 , 30%, 52% , Y300 , 62% and 
70% , Y480 , 80%. Not a single batch from F1 
to F9 met all the three selection criteria. But for 
microspheres, drug content is an important parameter 
because it determines the quantity of microspheres 
required to deliver the dose of a drug. The microspheres 
of batch F2 exhibited higher drug entrapment efficiency 
(79.20% w/v). The microspheres showed small, discrete, 
good spherical geometry as shown in Figures 5 and 6. To 
lower the loading dose and obtain desired release profile, 
batch F2 microspheres were coated with enteric polymer 
ethylcellulose. Batch C3 microspheres showed the desired 
in vitro release profile compared to that of batch C1, C2, 
Figure 1: Response surface plot for % drug loading Figure 2: Response surface plot for Y60
Figure 3: Response surface plot for t50 Figure 4: Response surface plot for t80J Young Pharm Vol 2 / No 1  33
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and market formulation [Figure 7]. It means that the 
batch C3 product mimic the release profile of DH of 
market formulation.
Stability studies
Stability studies reveled that polymers used were 
stable and compatible with the drug and no significant 
difference were found in physical appearance, particle 
size and shape, drug content, and in vitro drug release 
during stability study, and similarity factor f2 and 
dissimilarity factor f1 were found to be 0.96 and 0.15, 
respectively.
CONCLUSION
From the present investigation it was concluded that 
ethylcellulose-coated egg albumin microsphere, can be 
considered as an effectively coated carrier for the design 
of a controlled drug delivery system of highly water-
soluble DH.
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